Well, to your point, I called the CFO of COLY a few weeks ago after I had bought some shares and wanted to buy more. He was rather short with me when it came to the questions I was asking and basically told me that biotech investing was very complex and that is why institutions have experts and people like me (I inferred this) should stay away.
Well, as it turned out, I was perfectly able to discern value in the market and the rest is history.
Bottom line, you listen, you weigh it out, you decide, you don't point a finger, especially at yourself.
Bought today at .9101
